Latest Abliva News & Updates

See the latest news and media coverage for Abliva. We track all announcements, press releases, and industry mentions in real time, all in one place.

Abliva

Mitochondrial health therapeutics developer

Latest news about Abliva

16 December 2024 The Pharma Letter

Abliva acquisition ups rare disease focus for Pharming

Dutch biotech Pharming (Euronext: PHARM) has announced a public cash offer to acquire all outstanding shares of Swedish firm Abliva (STO: ABLI) for $66 million...
18 July 2024 TMCnet

Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease

-Abliva to host conference call and webcast on Friday 19 July at 4:30 pm CET / 10:30 am ET – LUND, Sweden, July 18, 2024...
13 May 2024 TMCnet

Abliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024

LUND, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe...
17 November 2023 PharmaBiz

Abliva, Owl Therapeutics sign licensing and collaboration agreement for NeuroSTAT in traumatic brain injury

Abliva AB and US-based Owl Therapeutics announced the signing of a licensing and collaboration agreement for Abliva’s NeuroSTAT for the treatment of moderate to severe...

Never miss news about Abliva

Track Abliva and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Discover what's making headlines across other trending companies.